

How Much is Your IND Going to Cost?

Michelle Higgin, Ph.D. Principal, PharmaDirections, Inc.

Drug development budgeting (over)simplified.

Easy: Its **\$3M** for a basic chronic, orally administered small molecule program using rats and dogs as the toxicology species and assuming *no existing staff* of toxicologists, process chemists, formulators and regulators just waiting for something to do. However, few programs actually meet these basic criteria, and many factors will impact this number, up and down. They include:

Factor	Cost (\$\$)	Comment
Need to use non-human primates (monkeys)	\bigcirc	Add ~\$250K
Formulation is IV	\bigcirc	Add \$150-\$250 for sterile manufacturing
API is commercially available with a DMF	0	Subtract \$300 - \$500K
Inhalation program	$\bigcirc \bigcirc$	Keep on adding
Sweat equity	0	If you have the diverse technical competence and can do the management, go for it and save as much as 400K
Acute administration only	S	Save \$100K or so.
Oncology indication	O	No <u>genotox</u> or safety pharmacology studies needed. Save \$200K
Therapeutic biologic	\bigcirc	CMC costs go way up. Add \$500K
Peptide		Add for CMC work but save on DMPK, break even.
		API costs are extremely variable. estimate –get a quote!
		he fox program

he tox program \$1.5M

but that is all it is. A good o budget effectively. One ise something unexpected rcent in the budget so you ther activities.

STRUCTURED FOR SCIENCE. BUILT FOR SPEED.

5001 Weston Parkway, Suite 103 • Cary, NC 27513 • www.PharmaDirections.com